Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Cerbomed opens up new markets: From March on t-VNS with NEMOS will be available in Italy for the treatment of epilepsies


Print article Print article
© Business Wire 2013
2013-02-21 14:10:44 -

More than 500,000 patients suffer from epilepsy in Italy. Not all of them can be treated sufficiently with available anticonvulsive medication. Therefore the medical device company cerbomed GmbH from Erlangen, Germany, announces that, from March 2013 on, transcutaneous vagus nerve stimulation (t-VNS) with NEMOS will be available to Italian epilepsy patients. To address the Italian market, cerbomed is cooperating with MARVAMED, a medical devices sales specialist experienced in the Italian neurology market. This is the first, successful step in extending into new European markets. Cooperations with further European distributors should follow in the course of the year.

MARVAMED's managing director, Dr. Pierluigi Bertolotto, has more than 20 years’ experience in neuromodulation and neurosurgery. He has both technical know-how and a network

with experts in the field of epilepsy.
His company, MARVAMED, based in Genoa, is a distributor specializing in medical products for neuromodulation and functional neurosurgery.

"Hard-to-treat epilepsy patients suffer severely, and currently there are only a few therapy alternatives. I am glad to announce that with the transcutaneous vagus nerve stimulator NEMOS, a promising therapy option is now available in Italy, too", Bertolotto declares.

"We are happy to cooperate with MARVAMED. Such an effective and experienced sales partner will let us offer t-VNS with NEMOS to patients in Italy", says Dr. Andreas Hartlep, Chief Executive Officer of cerbomed GmbH.


About t-VNS with NEMOS

Transcutaneous Vagus Nerve Stimulation : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. is addressed to patients suffering from various difficult-to-treat neurological and psychiatric diseases. The t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.

With NEMOS : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. cerbomed developed and patented a special stimulator and a dedicated ear electrode for treatment of epilepsies with t-VNS. The stimulator, which is connected with the ear electrode, sends out the electrical impulses. With the transcutaneous vagus nerve stimulator NEMOS a targeted stimulation of the vagus nerve gets possible without the need of a surgery.


About cerbomed

Cerbomed : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.

In 2010 cerbomed received the European clearance (CE mark) for the transcutaneous Vagus Nerve Stimulation for the treatment of epilepsies and depression, in 2012 for the treatment of pain.

Currently two clinical studies are carried out regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.

In September 2012 cerbomed entered into a strategic partnership with Cyberonics, Inc., the global market leader in vagus nerve stimulation.

NEMOS is already available for treating epilepsies in Germany and Austria, and in Italy from March 2013. Forthcoming cooperations with other distributors should make NEMOS available to epilepsy patients in Great Britain, France and Spain.

Please visit us on www.cerbomed.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .


About MARVAMED

MARVAMED, based in Genoa, is a distributor specializing in medical products for neuromodulation and functional neurosurgery. The company was founded in March 2010 by Dr. Pierluigi Bertolotto, who has 20 years of experience in the neurology market, in the area of movement disturbances and pain.

" title="http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130221005696r1&sid=16929&distro=ftp\"/>" target="_blank" rel="nofollow">cts.businesswire.com/ct/CT?id=bwnews&sty=20130221005696r1&am ..

Dr. Martin Hyca, Director Marketing & Salescerbomed GmbHPhone:

0049 9131 9202 76 30 martin.hyca@cerbomed.com : mailto:martin.hyca@cerbomed.com orDr.

Pierluigi Bertolotto, CEOMARVAMEDPhone: 0039 335481087 bertolotto@marvamed.com : mailto:bertolotto@marvamed.com


Author:
Hossam Abdel-Kader
e-mail
Web: www.pr-inside.com/
Phone: +43 1 9582319

Disclaimer: (c) 2013 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser